Advanced Biomed Inc Cash Provided by (Used in) Financing Activities, Discontinued Operations
Advanced Biomed Inc (ADVB) reported Cash Provided by (Used in) Financing Activities, Discontinued Operations of $641.76 thousand for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Financing Activities
us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations · last filed 2026-05-15
- Advanced Biomed Inc cash provided by (used in) financing activities, discontinued operations for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Advanced Biomed Inc cash provided by (used in) financing activities, discontinued operations for the quarter ending 2025-03-31 was $4.72K.
| Period end | Cash Provided by (Used in) Financing Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 9 month |
|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $641.76K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $641.76K 10-Q · filed 2026-02-13 | ||
| 2025-03-31 | $4.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $334.68K 10-Q · filed 2026-05-15 | |
| 2024-12-31 | $329.96K 10-Q · filed 2026-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |